Get started
Author

Haige Shen

Observed name: Shen, Haige
OpenAlex ID: A5011950780
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
2020 · You Lu, Jianxin Xue, et al. · Nature Medicine · 543
Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema
2014 · Ursula Schmidt-Erfurth, Gabriele E. Lang, et al. · Ophthalmology · 324
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.
2024 · Vanesa Gregorc, Maria González-Cao, et al. · Journal of Clinical Oncology · 28
PDF
A phase I randomized, double‐blinded , placebo‐controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects
2023 · Jason Lickliter, Shuang Wang, et al. · Clinical and Translational Science · 23
PDF
A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors.
2025 · Xinghao Ai, Aiping Zhou, et al. · Journal of Clinical Oncology · 20
First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors
2024 · Ye Guo, Zishu Wang, et al. · BMC Cancer · 19
PDF
A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).
2023 · Hai-Qiang Mai, Ye Guo, et al. · Journal of Clinical Oncology · 13
First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies
2022 · Junyuan Qi, Keshu Zhou, et al. · Blood · 10
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
2026 · Vanesa Gregorc, Margarita Majem, et al. · The Lancet Oncology · 9
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
2020 · You Lu, Jianxin Xue, et al. · Nature Medicine · 7
PDF
GFH018, a small molecular inhibitor targeting TGF-βRI kinase, in patients with advanced solid tumors: Final results of the phase I study.
2023 · Ye Guo, Zishu Wang, et al. · Journal of Clinical Oncology · 3
PDF
Trans-study projection of genomic biomarkers in analysis of oncogene deregulation and breast cancer
2018 · Dan Merl, Joseph Lucas, et al. · Oxford University Press eBooks · 3
Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial
2026 · Xinghao Ai, Zhengbo Song, et al. · Nature Medicine · 2
Stochastic Variational Inference via Upper Bound
2019 · Ji, Chunlin, Shen, Haige · arXiv (Cornell University) · 1
PDF
A first-in-human (FiH) phase I study of GFS202A, a GDF15/IL-6 bispecific antibody, in advanced cancer patients (pts) with pre-cachexia or cachexia.
2026 · Hongyun Zhao, Da Li, et al. · Journal of Clinical Oncology
Preliminary efficacy of GFH375 in patients with advanced cholangiocarcinoma or colorectal cancer harboring KRAS G12D mutation.
2026 · Lingjun Zhu, Yanhong Deng, et al. · Journal of Clinical Oncology
PDF
Lecture 17: Gene Prediction
2003 · Pankaj Agarwal, Haige Shen
Works count: 26
Citation count: 1,000
H-index: 9
I10-index: 8
Year
Topic
Type